Efficacy News and Research

RSS

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

DiaGenic ASA and Pfizer Inc today signed an agreement for explorative R&D collaboration to identify biomarkers in early stages of Alzheimer's disease (AD) using DiaGenic's patented gene expression technology and its blood samples from ongoing clinical studies.

17 Dec 2010

23andMe project aims at validating highly scalable pharmacogenomics research

23andMe has launched a project funded by the National Institutes of Health which is aimed at validating 23andMe's highly-scalable platform for pharmacogenomics research. The company received $190,000 in stimulus funding from the American Recovery and Reinvestment Act of 2009 for "Web-based Phenotyping for Genome-Wide Association Studies of Drug Response" from NIH's National Human Genome Research Institute.

17 Dec 2010

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Viron Therapeutics Inc. today announced that the results of Viron's Phase 2a trial for VT-111 were published today in Circulation: Cardiovascular Interventions. In the study led by Dr. Jean-Claude Tardif, Director of the Research Centre at the Montreal Heart Institute, VT-111, also known as Serp-1, met both its primary and secondary endpoints of safety and biological activity in Acute Coronary Syndrome patients receiving coronary stents.

17 Dec 2010

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Alnylam Pharmaceuticals, a leading RNAi therapeutics company, presented new data at the 2010 International Chemical Congress of Pacific Basin Societies, being held in Honolulu, Hawaii, December 15-20.

17 Dec 2010

Repros prepares for dosing 3 mg cohort in low dose Proellex study in uterine fibroids and endometriosis

Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.

17 Dec 2010

Bayer's SAFYRAL oral contraceptive receives FDA approval

Bayer HealthCare Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new oral contraceptive (OC), SAFYRAL™ (drospirenone 3 mg/ ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL raises folate levels for the purpose of reducing the risk of rare neural tube defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing it.

17 Dec 2010

Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection

Anacor Pharmaceuticals announced today that enrollment has been initiated and the first patient has been dosed in the Phase 3 program of AN2690, a topical antifungal product candidate for the treatment of onychomycosis.

16 Dec 2010

Genetic breakthrough in lung cancer

For the study the team studied samples of lung tumors and nearby healthy lung tissue from 30 patients and examined the samples for the presence of messenger ribonucleic acid (mRNA) associated with 48 known genes for molecules called nuclear hormone receptors. Then they compared the active genes with patient outcomes and found that the expression of genes for certain nuclear hormone receptors helped predict patient survival.

16 Dec 2010

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Manhattan Pharmaceuticals, Inc. announced preliminary results today from a Phase 1/2 study of AST-915 for the treatment of essential tremor. Data from this single dose study demonstrated that AST-915 was safe and well tolerated and demonstrated a clear effect on tremor power.

16 Dec 2010

Omega-3 EPA or combination of EPA and DHA provide clear antidepressant benefits

Researchers at the University of Illinois at Chicago completed a review of previously published research on antidepressant benefits of Omega-3 essential fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The review comprised a meta-analysis of 15 randomized, double-blind, placebo-controlled studies in patients with depression and results were presented at the recent annual meeting of the American College of Neuropsychopharmacology.

16 Dec 2010

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Amarin Corporation plc, a clinical-stage biopharmaceutical company with a focus on cardiovascular disease, today reported the completion of patient randomization for its ANCHOR trial, a pivotal Phase 3 trial of AMR101. The Company indicated that it anticipates reporting top-line results from this trial in Q2 2011.

16 Dec 2010

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

Orexo AB and Boehringer Ingelheim announced today that Boehringer Ingelheim has selected a development candidate resulting from the worldwide exclusive research, development and commercialisation agreement which Boehringer Ingelheim had signed in November 2005 with Biolipox, a Swedish research-based pharmaceutical company acquired by Orexo in October 2007.

16 Dec 2010

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

BELLUS Health Inc. and Celtic Therapeutics announced today that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs in patients with long-lasting inflammatory conditions, most commonly due to rheumatoid arthritis. The study is designed to confirm the safety and efficacy of KIACTA™ in preventing renal function decline in patients with AA amyloidosis.

16 Dec 2010

ADVENTRX seeks meeting with FDA to discuss ANX-514 docetaxel emulsion study findings

ADVENTRX Pharmaceuticals, Inc. today announced it has submitted a request to the U.S. Food and Drug Administration (FDA) to schedule a meeting for the purpose of discussing its product candidate ANX-514 (docetaxel emulsion for injection). The FDA is expected to set the meeting date within 60 days of receiving the request from ADVENTRX.

16 Dec 2010

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Enzon Pharmaceuticals, today announced the initiation of Phase I clinical studies, in collaboration with the National Cancer Institute, for two of the Company's novel oncology product candidates, EZN-2968 and EZN-2208 (PEG-SN38).

16 Dec 2010

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

A synthetic derivative of the curry spice turmeric, made by scientists at the Salk Institute for Biological Studies, dramatically improves the behavioral and molecular deficits seen in animal models of ischemic stroke and traumatic brain injury.

16 Dec 2010

Study confirms Carrageenan as effective antiviral against H1N1 influenza strain

Carrageenan, is a polymer derived from red seaweed which helps to create a protective physical barrier in the nasal cavity and has proven to be an effective antiviral in the treatment of the common cold.

16 Dec 2010

Develogen enters license, collaboration agreement with MedImmune on insulin beta cell regeneration

Evotec AG today announced that via its subsidiary Develogen AG it has entered into a license and collaboration agreement with MedImmune (the global biologics unit of AstraZeneca), in the diabetes therapeutic area, with a particular focus on the regeneration of insulin producing beta cells. The license gives MedImmune exclusive access to a portfolio of research programs and represents the first deal executed by Evotec on beta cell regeneration assets and capabilities.

15 Dec 2010

CTT, Bayer sign Research and License Option Agreement

Cancer Targeted Technology (CTT), a Seattle-based biotechnology firm focusing on small molecule cancer enzyme inhibitors for the generation of novel diagnostics and therapeutics, today announced that it has signed a Research and License Option Agreement with Bayer Pharma AG, Germany. Under the agreement, CTT will work with Bayer to optimize a novel PET imaging agent based on its unique inhibitor scaffold that recognizes a validated cancer enzyme biomarker.

15 Dec 2010

Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis

Creabilis SA, a clinical stage European biotechnology company addressing unmet medical needs in dermatology, announced positive results in the Phase IIa study of its lead product CT327 in atopic dermatitis.

15 Dec 2010

Efficacy News and Research

Diagenic, Pfizer enter collaboration to identify biomarkers in early stages of Alzheimer's disease

23andMe project aims at validating highly scalable pharmacogenomics research

Viron's Phase 2a trial for VT-111 meets primary, secondary endpoints in ACS patients

Alnylam Pharmaceuticals progress in delivery and translation of RNAi therapeutics

Repros prepares for dosing 3 mg cohort in low dose Proellex study in uterine fibroids and endometriosis

Bayer's SAFYRAL oral contraceptive receives FDA approval

Anacor Pharmaceuticals initiates AN2690 phase 3 program for onychomycosis fungal infection

Genetic breakthrough in lung cancer

Manhattan Pharmaceuticals reports preliminary results from AST-915 Phase 1/2 study in essential tremor

Omega-3 EPA or combination of EPA and DHA provide clear antidepressant benefits

Amarin completes patient randomization in AMR101 Phase 3 trial in patients with high triglyceride levels

Boehringer Ingelheim's selection of development candidate triggers € 6.5 million milestone payment to Orexo

BELLUS Health, Celtic Therapeutics initiate KIACTA global confirmatory phase III clinical study for AA amyloidosis

ADVENTRX seeks meeting with FDA to discuss ANX-514 docetaxel emulsion study findings

Enzon in collaboration with NCI initiates EZN-2968, EZN-2208 Phase I studies for arresting tumor growth

Synthetic derivative of curry spice can be effective neuroprotective for stroke and TBI

Study confirms Carrageenan as effective antiviral against H1N1 influenza strain

Develogen enters license, collaboration agreement with MedImmune on insulin beta cell regeneration

CTT, Bayer sign Research and License Option Agreement

Positive results from Creabilis CT327 Phase IIa study in atopic dermatitis

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News